PubMed:18842961
Annnotations
Glycan-Motif
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 90-112 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | globotriaosyl ceramide |
| T2 | 173-194 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | globotriaosylceramide |
| T3 | 196-201 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T4 | 291-296 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T5 | 387-392 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T6 | 402-407 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T7 | 656-661 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T8 | 681-697 | https://glytoucan.org/Structures/Glycans/G71142DF | denotes | glucosylceramide |
| T9 | 791-796 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T10 | 917-922 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T11 | 1049-1054 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T12 | 1407-1412 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T13 | 1480-1485 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T14 | 1584-1589 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T15 | 1705-1710 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T16 | 1758-1763 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T17 | 1882-1887 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
GlyCosmos6-Glycan-Motif-Image
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 90-112 | Glycan_Motif | denotes | globotriaosyl ceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T2 | 173-194 | Glycan_Motif | denotes | globotriaosylceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T3 | 196-201 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T4 | 291-296 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T5 | 387-392 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T6 | 402-407 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T7 | 656-661 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T8 | 681-697 | Glycan_Motif | denotes | glucosylceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G71142DF |
| T9 | 791-796 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T10 | 917-922 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T11 | 1049-1054 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T12 | 1407-1412 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T13 | 1480-1485 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T14 | 1584-1589 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T15 | 1705-1710 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T16 | 1758-1763 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
| T17 | 1882-1887 | Glycan_Motif | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO |
GlyCosmos6-Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 90-112 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | globotriaosyl ceramide |
| T2 | 173-194 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | globotriaosylceramide |
| T3 | 196-201 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T4 | 291-296 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T5 | 387-392 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T6 | 402-407 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T7 | 656-661 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T8 | 681-697 | https://glytoucan.org/Structures/Glycans/G71142DF | denotes | glucosylceramide |
| T9 | 791-796 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T10 | 917-922 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T11 | 1049-1054 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T12 | 1407-1412 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T13 | 1480-1485 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T14 | 1584-1589 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T15 | 1705-1710 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T16 | 1758-1763 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
| T17 | 1882-1887 | https://glytoucan.org/Structures/Glycans/G00059MO | denotes | Gb(3) |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-120 | Sentence | denotes | Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. |
| TextSentencer_T2 | 121-518 | Sentence | denotes | To examine the role of the glycosphingolipid (GSL), globotriaosylceramide (Gb(3), CD77, p(k) blood group antigen) in HIV-1 infection, we have pharmacologically modulated Gb(3) metabolism in an X4 HIV-1 infectable monocytic cell line (THP-1) that naturally expresses Gb(3) and in a Gb(3)-expressing glioblastoma cell line (U87) transfected to express both CD4 and CCR5 to permit R5 HIV-1 infection. |
| TextSentencer_T3 | 519-797 | Sentence | denotes | THP-1 and U87 cells were treated with either a competitive inhibitor of alpha-galactosidase A, 1-deoxygalactonojirimycin (DGJ) to induce Gb(3) accumulation, or a glucosylceramide synthase inhibitor, phenyl-2-palmitylamino-3-pyrrolidino-1-propanol (P4) to deplete cells of Gb(3). |
| TextSentencer_T4 | 798-888 | Sentence | denotes | HIV susceptibility was determined via measurement of p24(gag) antigen production by ELISA. |
| TextSentencer_T5 | 889-1017 | Sentence | denotes | In addition, total cellular Gb(3) content was determined using thin layer chromatography followed by Verotoxin1 overlay binding. |
| TextSentencer_T6 | 1018-1085 | Sentence | denotes | The cell surface expression of Gb(3) was verified by FACS analysis. |
| TextSentencer_T7 | 1086-1264 | Sentence | denotes | We found that DGJ significantly decreased THP-1 and U87 cell susceptibility to HIV-1(IIIB) and HIV-1(BaL) infection, respectively, at a concentration of approximately 100 microM. |
| TextSentencer_T8 | 1265-1359 | Sentence | denotes | In contrast, P4 (2 microM) substantially increased cellular susceptibility to HIV-1 infection. |
| TextSentencer_T9 | 1360-1530 | Sentence | denotes | Total cellular GSL analysis verified increased Gb(3) expression in cells treated with DGJ and considerable reduction of Gb(3) in P4-treated cells as compared to controls. |
| TextSentencer_T10 | 1531-1660 | Sentence | denotes | These results show a reciprocal relationship between Gb(3) expression and infection with either X4 HIV-1(IIIB) or R5 HIV-1(Ba-L). |
| TextSentencer_T11 | 1661-1748 | Sentence | denotes | These results support previous studies that Gb(3) provides resistance to HIV infection. |
| TextSentencer_T12 | 1749-1950 | Sentence | denotes | Variable Gb(3) expression may provide a natural HIV resistance factor in the general population, and pharmacological manipulation of Gb(3) levels may provide an approach to induction of HIV resistance. |
| T1 | 0-120 | Sentence | denotes | Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. |
| T2 | 121-518 | Sentence | denotes | To examine the role of the glycosphingolipid (GSL), globotriaosylceramide (Gb(3), CD77, p(k) blood group antigen) in HIV-1 infection, we have pharmacologically modulated Gb(3) metabolism in an X4 HIV-1 infectable monocytic cell line (THP-1) that naturally expresses Gb(3) and in a Gb(3)-expressing glioblastoma cell line (U87) transfected to express both CD4 and CCR5 to permit R5 HIV-1 infection. |
| T3 | 519-797 | Sentence | denotes | THP-1 and U87 cells were treated with either a competitive inhibitor of alpha-galactosidase A, 1-deoxygalactonojirimycin (DGJ) to induce Gb(3) accumulation, or a glucosylceramide synthase inhibitor, phenyl-2-palmitylamino-3-pyrrolidino-1-propanol (P4) to deplete cells of Gb(3). |
| T4 | 798-888 | Sentence | denotes | HIV susceptibility was determined via measurement of p24(gag) antigen production by ELISA. |
| T5 | 889-1017 | Sentence | denotes | In addition, total cellular Gb(3) content was determined using thin layer chromatography followed by Verotoxin1 overlay binding. |
| T6 | 1018-1085 | Sentence | denotes | The cell surface expression of Gb(3) was verified by FACS analysis. |
| T7 | 1086-1264 | Sentence | denotes | We found that DGJ significantly decreased THP-1 and U87 cell susceptibility to HIV-1(IIIB) and HIV-1(BaL) infection, respectively, at a concentration of approximately 100 microM. |
| T8 | 1265-1359 | Sentence | denotes | In contrast, P4 (2 microM) substantially increased cellular susceptibility to HIV-1 infection. |
| T9 | 1360-1530 | Sentence | denotes | Total cellular GSL analysis verified increased Gb(3) expression in cells treated with DGJ and considerable reduction of Gb(3) in P4-treated cells as compared to controls. |
| T10 | 1531-1660 | Sentence | denotes | These results show a reciprocal relationship between Gb(3) expression and infection with either X4 HIV-1(IIIB) or R5 HIV-1(Ba-L). |
| T11 | 1661-1748 | Sentence | denotes | These results support previous studies that Gb(3) provides resistance to HIV infection. |
| T12 | 1749-1950 | Sentence | denotes | Variable Gb(3) expression may provide a natural HIV resistance factor in the general population, and pharmacological manipulation of Gb(3) levels may provide an approach to induction of HIV resistance. |
| T1 | 0-120 | Sentence | denotes | Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. |
| T2 | 121-518 | Sentence | denotes | To examine the role of the glycosphingolipid (GSL), globotriaosylceramide (Gb(3), CD77, p(k) blood group antigen) in HIV-1 infection, we have pharmacologically modulated Gb(3) metabolism in an X4 HIV-1 infectable monocytic cell line (THP-1) that naturally expresses Gb(3) and in a Gb(3)-expressing glioblastoma cell line (U87) transfected to express both CD4 and CCR5 to permit R5 HIV-1 infection. |
| T3 | 519-797 | Sentence | denotes | THP-1 and U87 cells were treated with either a competitive inhibitor of alpha-galactosidase A, 1-deoxygalactonojirimycin (DGJ) to induce Gb(3) accumulation, or a glucosylceramide synthase inhibitor, phenyl-2-palmitylamino-3-pyrrolidino-1-propanol (P4) to deplete cells of Gb(3). |
| T4 | 798-888 | Sentence | denotes | HIV susceptibility was determined via measurement of p24(gag) antigen production by ELISA. |
| T5 | 889-1017 | Sentence | denotes | In addition, total cellular Gb(3) content was determined using thin layer chromatography followed by Verotoxin1 overlay binding. |
| T6 | 1018-1085 | Sentence | denotes | The cell surface expression of Gb(3) was verified by FACS analysis. |
| T7 | 1086-1264 | Sentence | denotes | We found that DGJ significantly decreased THP-1 and U87 cell susceptibility to HIV-1(IIIB) and HIV-1(BaL) infection, respectively, at a concentration of approximately 100 microM. |
| T8 | 1265-1359 | Sentence | denotes | In contrast, P4 (2 microM) substantially increased cellular susceptibility to HIV-1 infection. |
| T9 | 1360-1530 | Sentence | denotes | Total cellular GSL analysis verified increased Gb(3) expression in cells treated with DGJ and considerable reduction of Gb(3) in P4-treated cells as compared to controls. |
| T10 | 1531-1660 | Sentence | denotes | These results show a reciprocal relationship between Gb(3) expression and infection with either X4 HIV-1(IIIB) or R5 HIV-1(Ba-L). |
| T11 | 1661-1748 | Sentence | denotes | These results support previous studies that Gb(3) provides resistance to HIV infection. |
| T12 | 1749-1950 | Sentence | denotes | Variable Gb(3) expression may provide a natural HIV resistance factor in the general population, and pharmacological manipulation of Gb(3) levels may provide an approach to induction of HIV resistance. |
Glycosmos6-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 214-219 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
| T2 | 214-219 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
GlycoBiology-GDGDB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 167-170 | http://acgg.asia/db/diseases/gdgdb?con_ui=CON00023 | denotes | GSL |
| _T2 | 1375-1378 | http://acgg.asia/db/diseases/gdgdb?con_ui=CON00023 | denotes | GSL |
GlycoBiology-FMA
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 148-165 | FMAID:82815 | denotes | glycosphingolipid |
| _T2 | 148-165 | FMAID:196810 | denotes | glycosphingolipid |
| _T3 | 148-165 | FMAID:82813 | denotes | glycosphingolipid |
| _T4 | 148-165 | FMAID:196808 | denotes | glycosphingolipid |
| _T5 | 148-165 | FMAID:196813 | denotes | glycosphingolipid |
| _T6 | 148-165 | FMAID:82818 | denotes | glycosphingolipid |
| _T7 | 148-165 | FMAID:196815 | denotes | glycosphingolipid |
| _T8 | 148-165 | FMAID:82819 | denotes | glycosphingolipid |
| _T9 | 148-165 | FMAID:196814 | denotes | glycosphingolipid |
| _T10 | 148-165 | FMAID:196807 | denotes | glycosphingolipid |
| _T11 | 148-165 | FMAID:82812 | denotes | glycosphingolipid |
| _T12 | 148-165 | FMAID:82817 | denotes | glycosphingolipid |
| _T13 | 148-165 | FMAID:196812 | denotes | glycosphingolipid |
| _T14 | 148-165 | FMAID:196809 | denotes | glycosphingolipid |
| _T15 | 148-165 | FMAID:82811 | denotes | glycosphingolipid |
| _T16 | 148-165 | FMAID:196806 | denotes | glycosphingolipid |
| _T17 | 148-165 | FMAID:82814 | denotes | glycosphingolipid |
| _T18 | 214-219 | FMAID:256053 | denotes | blood |
| _T19 | 334-343 | FMAID:167164 | denotes | monocytic |
| _T20 | 334-343 | FMAID:62864 | denotes | monocytic |
| _T21 | 533-538 | FMAID:169002 | denotes | cells |
| _T22 | 533-538 | FMAID:68646 | denotes | cells |
| _T23 | 597-610 | FMAID:82794 | denotes | galactosidase |
| _T24 | 597-610 | FMAID:196789 | denotes | galactosidase |
| _T25 | 681-697 | FMAID:196816 | denotes | glucosylceramide |
| _T26 | 681-697 | FMAID:82820 | denotes | glucosylceramide |
| _T27 | 782-787 | FMAID:68646 | denotes | cells |
| _T28 | 782-787 | FMAID:169002 | denotes | cells |
| _T29 | 855-858 | FMAID:167404 | denotes | gag |
| _T30 | 1022-1034 | FMAID:200942 | denotes | cell surface |
| _T31 | 1022-1034 | FMAID:212684 | denotes | cell surface |
| _T32 | 1027-1034 | FMAID:50594 | denotes | surface |
| _T33 | 1027-1034 | FMAID:146300 | denotes | surface |
| _T34 | 1257-1263 | FMAID:165145 | denotes | microM |
| _T35 | 1284-1290 | FMAID:165145 | denotes | microM |
| _T36 | 1292-1305 | FMAID:188924 | denotes | substantially |
| _T37 | 1424-1432 | FMAID:199054 | denotes | in cells |
| _T38 | 1424-1432 | FMAID:84785 | denotes | in cells |
| _T39 | 1427-1432 | FMAID:68646 | denotes | cells |
| _T40 | 1427-1432 | FMAID:169002 | denotes | cells |
| _T41 | 1500-1505 | FMAID:68646 | denotes | cells |
| _T42 | 1500-1505 | FMAID:169002 | denotes | cells |
| _T43 | 1654-1656 | FMAID:228755 | denotes | Ba |
uniprot-human
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 355-358 | http://www.uniprot.org/uniprot/P10070 | denotes | THP |
| T2 | 519-522 | http://www.uniprot.org/uniprot/P10070 | denotes | THP |
| T3 | 1128-1131 | http://www.uniprot.org/uniprot/P10070 | denotes | THP |
| T4 | 355-358 | http://www.uniprot.org/uniprot/P07911 | denotes | THP |
| T5 | 519-522 | http://www.uniprot.org/uniprot/P07911 | denotes | THP |
| T6 | 1128-1131 | http://www.uniprot.org/uniprot/P07911 | denotes | THP |
| T7 | 476-479 | http://www.uniprot.org/uniprot/P01730 | denotes | CD4 |
| T8 | 484-488 | http://www.uniprot.org/uniprot/O14708 | denotes | CCR5 |
| T9 | 591-612 | http://www.uniprot.org/uniprot/P06280 | denotes | alpha-galactosidase A |
| T10 | 681-706 | http://www.uniprot.org/uniprot/Q16739 | denotes | glucosylceramide synthase |
| T11 | 851-854 | http://www.uniprot.org/uniprot/O94811 | denotes | p24 |
| T12 | 851-854 | http://www.uniprot.org/uniprot/P21926 | denotes | p24 |
| T13 | 851-854 | http://www.uniprot.org/uniprot/Q15363 | denotes | p24 |
uniprot-mouse
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 355-358 | http://www.uniprot.org/uniprot/Q91X17 | denotes | THP |
| T2 | 519-522 | http://www.uniprot.org/uniprot/Q91X17 | denotes | THP |
| T3 | 1128-1131 | http://www.uniprot.org/uniprot/Q91X17 | denotes | THP |
| T4 | 476-479 | http://www.uniprot.org/uniprot/P06332 | denotes | CD4 |
| T5 | 591-612 | http://www.uniprot.org/uniprot/P51569 | denotes | alpha-galactosidase A |
| T6 | 681-706 | http://www.uniprot.org/uniprot/O88693 | denotes | glucosylceramide synthase |
| T7 | 851-854 | http://www.uniprot.org/uniprot/P61022 | denotes | p24 |
| T8 | 851-854 | http://www.uniprot.org/uniprot/Q9CQM0 | denotes | p24 |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 220-225 | http://purl.bioontology.org/ontology/STY/T096 | denotes | group |
| T2 | 533-538 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
| T3 | 782-787 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
| T4 | 1427-1432 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
| T5 | 1500-1505 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 297-307 | http://purl.obolibrary.org/obo/GO_0008152 | denotes | metabolism |
| T2 | 591-610 | http://purl.obolibrary.org/obo/GO_0004557 | denotes | alpha-galactosidase |
| T3 | 908-916 | http://purl.obolibrary.org/obo/GO_0007349 | denotes | cellular |
| T4 | 1316-1324 | http://purl.obolibrary.org/obo/GO_0007349 | denotes | cellular |
| T5 | 1366-1374 | http://purl.obolibrary.org/obo/GO_0007349 | denotes | cellular |
GO-MF
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1009-1016 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
| T2 | 1009-1016 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
| T3 | 1009-1016 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
| T4 | 1009-1016 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
GO-CC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 31-35 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T2 | 344-348 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T3 | 432-436 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T4 | 1022-1026 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T5 | 533-538 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T6 | 782-787 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T7 | 1427-1432 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T8 | 1500-1505 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T9 | 1022-1034 | http://purl.obolibrary.org/obo/GO_0009986 | denotes | cell surface |
UBERON-AE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 214-219 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
GlycoBiology-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 214-219 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
| T2 | 214-219 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
GlycoBiology-Motifs
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 214-225 | http://rdf.glycoinfo.org/glycan/G00066MO | denotes | blood group |
GlycoBiology-Epitope
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-GlycoEpitope-B_T1 | 196-200 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T2 | 291-295 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T3 | 387-391 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T4 | 402-406 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T5 | 656-660 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T6 | 791-795 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T7 | 917-921 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T8 | 1049-1053 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T9 | 1407-1411 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T10 | 1480-1484 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T11 | 1584-1588 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T12 | 1705-1709 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T13 | 1758-1762 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
| PD-GlycoEpitope-B_T14 | 1882-1886 | http://www.glycoepitope.jp/epitopes/EP0071 | denotes | Gb(3 |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 214-219 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 54-63 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T2 | 244-253 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T3 | 419-431 | Disease | denotes | glioblastoma | http://purl.obolibrary.org/obo/MONDO_0018177|http://purl.obolibrary.org/obo/MONDO_0020690 |
| T5 | 508-517 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T6 | 1071-1075 | Disease | denotes | FACS | http://purl.obolibrary.org/obo/MONDO_0018262 |
| T7 | 1192-1201 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T8 | 1349-1358 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T9 | 1605-1614 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T10 | 1734-1747 | Disease | denotes | HIV infection | http://purl.obolibrary.org/obo/MONDO_0005109 |
GlyCosmos15-Glycan
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 196-201 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T2 | 291-296 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T3 | 387-392 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T4 | 402-407 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T5 | 656-661 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T6 | 791-796 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T7 | 917-922 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T8 | 1049-1054 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T9 | 1407-1412 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T10 | 1480-1485 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T11 | 1584-1589 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T12 | 1705-1710 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T13 | 1758-1763 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
| T14 | 1882-1887 | Glycan | denotes | Gb(3) | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO |
Anatomy-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 214-219 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/MAT_0000083|http://purl.obolibrary.org/obo/MAT_0000315 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 36-63 | Phenotype | denotes | susceptibility to infection | HP:0002719 |
| T2 | 419-431 | Phenotype | denotes | glioblastoma | HP:0012174 |
GlyCosmos15-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 36-63 | Phenotype | denotes | susceptibility to infection | HP:0002719 |
| T2 | 419-431 | Phenotype | denotes | glioblastoma | HP:0012174 |
GlyCosmos15-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-120 | Sentence | denotes | Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. |
| T2 | 121-518 | Sentence | denotes | To examine the role of the glycosphingolipid (GSL), globotriaosylceramide (Gb(3), CD77, p(k) blood group antigen) in HIV-1 infection, we have pharmacologically modulated Gb(3) metabolism in an X4 HIV-1 infectable monocytic cell line (THP-1) that naturally expresses Gb(3) and in a Gb(3)-expressing glioblastoma cell line (U87) transfected to express both CD4 and CCR5 to permit R5 HIV-1 infection. |
| T3 | 519-797 | Sentence | denotes | THP-1 and U87 cells were treated with either a competitive inhibitor of alpha-galactosidase A, 1-deoxygalactonojirimycin (DGJ) to induce Gb(3) accumulation, or a glucosylceramide synthase inhibitor, phenyl-2-palmitylamino-3-pyrrolidino-1-propanol (P4) to deplete cells of Gb(3). |
| T4 | 798-888 | Sentence | denotes | HIV susceptibility was determined via measurement of p24(gag) antigen production by ELISA. |
| T5 | 889-1017 | Sentence | denotes | In addition, total cellular Gb(3) content was determined using thin layer chromatography followed by Verotoxin1 overlay binding. |
| T6 | 1018-1085 | Sentence | denotes | The cell surface expression of Gb(3) was verified by FACS analysis. |
| T7 | 1086-1264 | Sentence | denotes | We found that DGJ significantly decreased THP-1 and U87 cell susceptibility to HIV-1(IIIB) and HIV-1(BaL) infection, respectively, at a concentration of approximately 100 microM. |
| T8 | 1265-1359 | Sentence | denotes | In contrast, P4 (2 microM) substantially increased cellular susceptibility to HIV-1 infection. |
| T9 | 1360-1530 | Sentence | denotes | Total cellular GSL analysis verified increased Gb(3) expression in cells treated with DGJ and considerable reduction of Gb(3) in P4-treated cells as compared to controls. |
| T10 | 1531-1660 | Sentence | denotes | These results show a reciprocal relationship between Gb(3) expression and infection with either X4 HIV-1(IIIB) or R5 HIV-1(Ba-L). |
| T11 | 1661-1748 | Sentence | denotes | These results support previous studies that Gb(3) provides resistance to HIV infection. |
| T12 | 1749-1950 | Sentence | denotes | Variable Gb(3) expression may provide a natural HIV resistance factor in the general population, and pharmacological manipulation of Gb(3) levels may provide an approach to induction of HIV resistance. |
GlyCosmos15-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 54-63 | Disease | denotes | infection | MONDO:0005550 |
| T2 | 244-253 | Disease | denotes | infection | MONDO:0005550 |
| T3 | 419-431 | Disease | denotes | glioblastoma | MONDO:0018177|MONDO:0020690 |
| T5 | 508-517 | Disease | denotes | infection | MONDO:0005550 |
| T6 | 1192-1201 | Disease | denotes | infection | MONDO:0005550 |
| T7 | 1349-1358 | Disease | denotes | infection | MONDO:0005550 |
| T8 | 1605-1614 | Disease | denotes | infection | MONDO:0005550 |
| T9 | 1734-1747 | Disease | denotes | HIV infection | MONDO:0005109 |
GlyCosmos15-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 214-219 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
GlyCosmos15-FMA
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 13-16 | Body_part | denotes | HIV | FMA:278683 |
| T2 | 214-219 | Body_part | denotes | blood | FMA:9670 |
| T3 | 238-241 | Body_part | denotes | HIV | FMA:278683 |
| T4 | 317-320 | Body_part | denotes | HIV | FMA:278683 |
| T5 | 334-343 | Body_part | denotes | monocytic | FMA:62864 |
| T6 | 502-505 | Body_part | denotes | HIV | FMA:278683 |
| T7 | 798-801 | Body_part | denotes | HIV | FMA:278683 |
| T8 | 1022-1034 | Body_part | denotes | cell surface | FMA:67653 |
| T9 | 1165-1168 | Body_part | denotes | HIV | FMA:278683 |
| T10 | 1181-1184 | Body_part | denotes | HIV | FMA:278683 |
| T11 | 1343-1346 | Body_part | denotes | HIV | FMA:278683 |
| T12 | 1630-1633 | Body_part | denotes | HIV | FMA:278683 |
| T13 | 1648-1651 | Body_part | denotes | HIV | FMA:278683 |
| T14 | 1734-1737 | Body_part | denotes | HIV | FMA:278683 |
| T15 | 1797-1800 | Body_part | denotes | HIV | FMA:278683 |
| T16 | 1935-1938 | Body_part | denotes | HIV | FMA:278683 |
GlyCosmos15-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 214-219 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/MAT_0000315 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 214-219 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
| T2 | 957-962 | Body_part | denotes | layer | http://purl.obolibrary.org/obo/UBERON_0000119|http://purl.obolibrary.org/obo/UBERON_0022303 |
CL-cell
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 334-343 | Cell | denotes | monocytic | http://purl.obolibrary.org/obo/CL:0000576|http://purl.obolibrary.org/obo/CL:0001054 |